m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03656
 [1], [2]
Histone modification H3K27me3 EZH2 miR-338-5p Indirect Enhancement m6A modification PARP1 PARP1 METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Poly [ADP-ribose] polymerase 1 (PARP1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone-lysine N-methyltransferase EZH2 (EZH2) WRITER View Details
Regulated Target Histone H3 lysine 27 trimethylation (H3K27me3) View Details
Downstream Gene miR-338-5p View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification indirectly regulates m6A modification through downstream signaling pathways
Crosstalk Summary Collectively, EZH2 downregulated hsa-miR-338-5p through Histone H3 lysine 27 trimethylation (H3K27me3), which in turn impaired miR-338-5p-dependent METTL3 inhibition and enhanced CDCP1 translation, therefore contributing to the development of GC. m6A methyltransferase METTL3 facilitates oxaliplatin resistance in CD133+ gastric cancer stem cells by Promoting Poly [ADP-ribose] polymerase 1 (PARP1) mRNA stability which increases base excision repair pathway activity. METTTL3 enhances the stability of PARP1 by recruiting YTHDF1 to target the 3'-untranslated Region (3'-UTR) of PARP1 mRNA.
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Responsed Drug Oxaliplatin
 Drug Info 
Pathway Response Nucleotide excision repair hsa03420
Signaling pathways regulating pluripotency of stem cells hsa04550
Cell Process RNA stability
Excision repair
In-vitro Model
 MKN74 Gastric tubular adenocarcinoma Homo sapiens CVCL_2791
HEK293T Normal Homo sapiens CVCL_0063
AGS Gastric adenocarcinoma Homo sapiens CVCL_0139
SNU-719 Gastric tubular adenocarcinoma Homo sapiens CVCL_5086
In-vivo Model 100,000 pLKO and PARP1-sh1 (PT1 and PT2) cells were mixed with matrix gel and inoculate into BALB/C nude mice, respectively. After 25 days, 6 organoid transplanted tumor mice were treated with oxaliplatin (Sellekchem, s1224) twice a week for 4 weeks at a dose of 5 mg/kg.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone-lysine N-methyltransferase EZH2 (EZH2) 74 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Tazemetostat Approved [3]
Synonyms
EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 2.5 nM
External Link
CID: 66558664
TTD: D00EQL
DrugBank: DB12887
 Compound Name DS-3201b Phase 2 [4]
Synonyms
Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 126481870
TTD: DNM79H
 Compound Name CPI-1205 Phase 1/2 [5]
Synonyms
HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 78320408
TTD: D0E6AG
DrugBank: DB14581
 Compound Name SHR2554 Phase 1/2 [6]
MOA Inhibitor
External Link
TTD: DM5X0L
 Compound Name CPI-0209 Phase 1/2 [7]
MOA Inhibitor
External Link
TTD: DXL38G
 Compound Name GSK2816126 Phase 1 [8]
Synonyms
GSK 126; GSK-126
    Click to Show/Hide
MOA Modulator
Activity Ki = 0.5 nM
External Link
CID: 68210102
TTD: D05FIJ
 Compound Name PF-06821497 Phase 1 [9]
Synonyms
UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 118572065
TTD: DI1L7M
DrugBank: DB14799
 Compound Name DS-3201 Phase 1 [5]
Synonyms
QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 22627096
TTD: D0LG8T
 Compound Name HH2853 Phase 1 [10]
MOA Inhibitor
External Link
TTD: D6EU7R
 Compound Name PMID28394193-Compound-33 Patented [11]
MOA Inhibitor
Activity IC50 = 100 nM
External Link
CID: 121305270
TTD: D03MYI
 Compound Name PMID28394193-Compound-Figure3bI Patented [11]
MOA Inhibitor
External Link
TTD: D04PCW
 Compound Name PMID28394193-Compound-35 Patented [11]
MOA Inhibitor
Activity IC50 = 10 nM
External Link
TTD: D05MAR
 Compound Name PMID28394193-Compound-54 Patented [11]
MOA Inhibitor
External Link
TTD: D07CZI
 Compound Name PMID28394193-Compound-24 Patented [11]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117807842
TTD: D08MXO
 Compound Name PMID28394193-Compound-27 Patented [11]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 76684269
TTD: D09GFF
 Compound Name PMID28394193-Compound-25 Patented [11]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117807842
TTD: D09PQQ
 Compound Name PMID28394193-Compound-50 Patented [11]
MOA Inhibitor
Activity IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link
CID: 118580552
TTD: D0A0VH
 Compound Name PMID28394193-Compound-47 Patented [11]
MOA Inhibitor
Activity IC50 = 2 nM; Ki < 1 nM
External Link
CID: 118616529
TTD: D0B4TX
 Compound Name PMID28394193-Compound-21 Patented [11]
MOA Inhibitor
External Link
TTD: D0BL8W
 Compound Name PMID28394193-Compound-41 Patented [11]
MOA Inhibitor
External Link
CID: 118101320
TTD: D0BT6Y
 Compound Name PMID28394193-Compound-53 Patented [11]
MOA Inhibitor
Activity IC50 = 80 nM
External Link
CID: 121322599
TTD: D0CH4O
 Compound Name PMID28394193-Compound-Figure5aVIII Patented [11]
MOA Inhibitor
External Link
TTD: D0D1QD
 Compound Name PMID28394193-Compound-38 Patented [11]
MOA Inhibitor
External Link
CID: 78320108
TTD: D0DQ6N
 Compound Name PMID28394193-Compound-51 Patented [11]
MOA Inhibitor
Activity IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link
CID: 118580509
TTD: D0FC9J
 Compound Name PMID28394193-Compound-31 Patented [11]
MOA Inhibitor
Activity IC50 = 20 nM
External Link
TTD: D0FI3A
 Compound Name PMID28394193-Compound-42 Patented [11]
MOA Inhibitor
External Link
CID: 118096643
TTD: D0H4HR
 Compound Name PMID28394193-Compound-15 Patented [11]
MOA Inhibitor
External Link
TTD: D0KR2T
 Compound Name PMID28394193-Compound-52 Patented [11]
MOA Inhibitor
Activity IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link
CID: 118580510
TTD: D0LR5O
 Compound Name PMID28394193-Compound-32 Patented [11]
MOA Inhibitor
Activity IC50 = 500 nM
External Link
TTD: D0M1TG
 Compound Name PMID28394193-Compound-23 Patented [11]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 117807623
TTD: D0M9BY
 Compound Name PMID28394193-Compound-29 Patented [11]
MOA Inhibitor
Activity IC50 = 100 nM
External Link
TTD: D0MH8G
 Compound Name PMID28394193-Compound-30 Patented [11]
MOA Inhibitor
Activity IC50 = 16 nM
External Link
TTD: D0MO2X
 Compound Name PMID28394193-Compound-39 Patented [11]
MOA Inhibitor
External Link
TTD: D0MZ8D
 Compound Name PMID28394193-Compound-49 Patented [11]
MOA Inhibitor
Activity IC50 > 1 nM; IC50 < 2 nM; Ki > 0.01 nM; Ki < 0.04 nM
External Link
CID: 118572078
TTD: D0PB6T
 Compound Name PMID28394193-Compound-43 Patented [11]
MOA Inhibitor
External Link
CID: 118096796
TTD: D0PI5O
 Compound Name PMID28394193-Compound-40 Patented [11]
MOA Inhibitor
External Link
CID: 118095598
TTD: D0QH1J
 Compound Name PMID28394193-Compound-Figure3bIII Patented [11]
MOA Inhibitor
External Link
TTD: D0R2TQ
 Compound Name PMID28394193-Compound-36 Patented [11]
MOA Inhibitor
Activity IC50 = 316 nM
External Link
TTD: D0RD5P
 Compound Name PMID28394193-Compound-28 Patented [11]
MOA Inhibitor
Activity IC50 = 32 nM
External Link
CID: 91884579
TTD: D0S4OP
 Compound Name PMID28394193-Compound-22 Patented [11]
MOA Inhibitor
External Link
TTD: D0SQ1R
 Compound Name PMID28394193-Compound-18 Patented [11]
MOA Inhibitor
External Link
TTD: D0SY6P
 Compound Name PMID28394193-Compound-16 Patented [11]
MOA Inhibitor
External Link
TTD: D0T8QL
 Compound Name PMID28394193-Compound-44 Patented [11]
MOA Inhibitor
External Link
CID: 118096614
TTD: D0U9OH
 Compound Name PMID28394193-Compound-20 Patented [11]
MOA Inhibitor
External Link
TTD: D0UG5O
 Compound Name PMID28394193-Compound-19 Patented [11]
MOA Inhibitor
External Link
TTD: D0VF0M
 Compound Name PMID28394193-Compound-37 Patented [11]
MOA Inhibitor
External Link
CID: 78320107
TTD: D0W2KL
 Compound Name PMID28394193-Compound-Figure3bII Patented [11]
MOA Inhibitor
External Link
TTD: D0W4MW
 Compound Name PMID28394193-Compound-26 Patented [11]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 75203283
TTD: D0Z0NC
 Compound Name PMID28394193-Compound-17 Patented [11]
MOA Inhibitor
External Link
TTD: D0Z0QS
 Compound Name PMID28394193-Compound-34 Patented [11]
MOA Inhibitor
Activity IC50 = 100 nM
External Link
TTD: D0Z7GN
 Compound Name PMID28394193-Compound-56 Patented [11]
MOA Inhibitor
Activity IC50 = 0.93 nM
External Link
TTD: D01PZZ
 Compound Name PMID28394193-Compound-46 Patented [11]
MOA Inhibitor
Activity IC50 = 5 nM
External Link
CID: 102593999
TTD: D0D4UH
 Compound Name PMID28394193-Compound-57 Patented [11]
MOA Inhibitor
Activity IC50 = 6.45 nM
External Link
TTD: D0G1JR
 Compound Name PMID28394193-Compound-14 Patented [11]
MOA Inhibitor
Activity IC50 = 21900 nM
External Link
CID: 90467336
TTD: D0GT7A
 Compound Name PMID28394193-Compound-12 Patented [11]
MOA Inhibitor
Activity IC50 < 10 nM
External Link
TTD: D0H8VN
 Compound Name PMID26882240-Compound-1 Patented [12]
MOA Inhibitor
External Link
CID: 5712
TTD: D0L1TA
 Compound Name PMID28394193-Compound-55 Patented [11]
MOA Inhibitor
Activity IC50 = 8.13 nM
External Link
TTD: D0M4LK
 Compound Name PMID28394193-Compound-45 Patented [11]
MOA Inhibitor
Activity IC50 = 168000 nM
External Link
CID: 118607675
TTD: D0M8AA
 Compound Name PMID28394193-Compound-13 Patented [11]
MOA Inhibitor
Activity IC50 = 1470 nM
External Link
CID: 86765324
TTD: D0TA4N
 Compound Name EPZ005687 Investigative [13]
Synonyms
EPZ-005687; EPZ 005687
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 60160561
TTD: D02BBA
 Compound Name EI1 Investigative [14]
Synonyms
KB-145943
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72199293
TTD: D02CIT
 Compound Name UNC1999 Investigative [15]
Synonyms
UNC 1999; UNC-1999
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72551585
TTD: D02YXP
 Compound Name MS1943 Investigative [6]
Synonyms
2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide
    Click to Show/Hide
MOA Degrader
External Link
CID: 139211327
TTD: D65IMT
 Compound Name GSK343 Investigative [16]
Synonyms
compound 6 [PMID 24900432]; GSK 343
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 174 nM
External Link
CID: 71268957
TTD: D02TVQ
 Compound Name PMID28394193-Compound-11 Patented [17]
External Link
TTD: D0MH5C
 Compound Name PMID28394193-Compound-10 Patented [17]
External Link
TTD: D0MZ9P
 Compound Name PMID28394193-Compound-14 Patented [11]
MOA Inhibitor
Activity IC50 = 21900 nM
External Link
CID: 90467336
TTD: D0GT7A
 Compound Name PMID28394193-Compound-12 Patented [11]
MOA Inhibitor
Activity IC50 < 10 nM
External Link
TTD: D0H8VN
 Compound Name PMID28394193-Compound-13 Patented [11]
MOA Inhibitor
Activity IC50 = 1470 nM
External Link
CID: 86765324
TTD: D0TA4N
 Compound Name PMID28394193-Compound-56 Patented [11]
MOA Inhibitor
Activity IC50 = 0.93 nM
External Link
TTD: D01PZZ
 Compound Name PMID28394193-Compound-46 Patented [11]
MOA Inhibitor
Activity IC50 = 5 nM
External Link
CID: 102593999
TTD: D0D4UH
 Compound Name PMID28394193-Compound-57 Patented [11]
MOA Inhibitor
Activity IC50 = 6.45 nM
External Link
TTD: D0G1JR
 Compound Name PMID28394193-Compound-55 Patented [11]
MOA Inhibitor
Activity IC50 = 8.13 nM
External Link
TTD: D0M4LK
 Compound Name PMID28394193-Compound-45 Patented [11]
MOA Inhibitor
Activity IC50 = 168000 nM
External Link
CID: 118607675
TTD: D0M8AA
Poly [ADP-ribose] polymerase 1 (PARP1) 131 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Nicotinamide Approved [18]
Synonyms
Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide
    Click to Show/Hide
MOA Binder
Activity IC50 = 210000 nM
External Link
CID: 936
TTD: D06NVJ
DrugBank: DB02701
 Compound Name KU-0058948 Approved [19]
Synonyms
CHEMBL380648; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7 nM
External Link
CID: 11291932
TTD: D09LSX
DrugBank: DB08058
 Compound Name Niraparib Tosylate Approved [20]
Synonyms
1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059
    Click to Show/Hide
MOA Modulator
External Link
CID: 78357761
TTD: D0DN0W
 Compound Name Nicaraven Phase 3 [21]
Synonyms
AVS; Antevan; Antevas
    Click to Show/Hide
MOA Modulator
External Link
CID: 71234
TTD: D0Z2UW
DrugBank: DB06397
 Compound Name CC-486 Phase 3 [22]
Synonyms
AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 5.8 nM
External Link
CID: 9840076
TTD: D09NTC
 Compound Name AG140699 Phase 2 [23]
MOA Inhibitor
External Link
TTD: D06KZL
 Compound Name AZD5305 Phase 2 [24]
Synonyms
16MZ1V3RBT; 2589531-76-8; 2-Pyridinecarboxamide, 5-(4-((7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl)-1-piperazinyl)-N-methyl-; 2-Pyridinecarboxamide, 5-[4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methyl-; 5-(4-((7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide; 5-[4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methylpicolinamide; 5-[4-[(7-ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide; 5-{4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3- yl)methyl]piperazin-1-yl}-N-methylpyridine-2- carboxamide; AC-37130; Azd 5305; AZD 5305 [WHO-DD]; AZD5305; AZD-5305; AZD-5305 [WHO-DD]; CHEMBL5095220; CS-0163534; E80364; EX-A5234; example 4 [WO2021013735]; GTPL11526; HY-132167; MS-26971; NSC834196; NSC-834196; Saruparib; saruparib [INN]; SCHEMBL22912701; SY295016; UNII-16MZ1V3RBT
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 155586901
TTD: D0YTM9
 Compound Name PMID27841036-Compound-37 Phase 2 [25]
Synonyms
2X-121
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2 nM
External Link
CID: 135565981
TTD: D0F5TD
 Compound Name Stenoparib Phase 2 [26]
MOA Inhibitor
External Link
TTD: DP48WE
 Compound Name AMXI 5001 Phase 1/2 [27]
MOA Inhibitor
External Link
TTD: D8TE4F
 Compound Name NMS-03305293 Phase 1 [28]
Synonyms
NMS-P293
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: DO0LP3
 Compound Name 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-6
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 230 nM
External Link
TTD: D01KFW
 Compound Name Benzimidazole carboxamide derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-I
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1 nM
External Link
TTD: D01PYO
 Compound Name PMID27841036-Compound-33 Patented [25]
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 56649297
TTD: D02KMI
 Compound Name 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4 Patented [25]
Synonyms
PMID27841036-Compound-9
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 44 nM
External Link
TTD: D02QFM
 Compound Name Phthalazine ketone derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-16
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6000 nM
External Link
CID: 89608436
TTD: D05ZBB
 Compound Name Quinazolinedione derivative 3 Patented [25]
Synonyms
PMID27841036-Compound-13
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 140 nM
External Link
CID: 59663666
TTD: D08KAH
 Compound Name 4-Carboxamido-isoindolinone derivative 2 Patented [25]
Synonyms
PMID27841036-Compound-3
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 11 nM
External Link
TTD: D08YPU
 Compound Name 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3 Patented [25]
Synonyms
PMID27841036-Compound-8
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 15 nM; Kd < 10 nM
External Link
TTD: D09HUV
 Compound Name 7-azaindole derivative 8 Patented [25]
Synonyms
PMID27841036-Compound-10
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 100 nM
External Link
CID: 73669300
TTD: D09WUA
 Compound Name 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5 Patented [25]
Synonyms
PMID27841036-Compound-IV
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D09ZIM
 Compound Name Phthalazine ketone derivative 3 Patented [25]
Synonyms
PMID27841036-Compound-18
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 9000 nM
External Link
CID: 71598692
TTD: D0AN7Z
 Compound Name Dihydropyrido phthalazinone derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-21
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 800 nM
External Link
CID: 136265073
TTD: D0B3QI
 Compound Name Phthalazine ketone derivative 2 Patented [25]
Synonyms
PMID27841036-Compound-17
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8000 nM
External Link
CID: 71571973
TTD: D0B4FV
 Compound Name Tricyclic indole compound 13 Patented [25]
Synonyms
PMID27841036-Compound-XVI
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 to 270 nM
External Link
TTD: D0E9JI
 Compound Name 3-phenyl isoquinolin-1(2H) derivative 2 Patented [25]
Synonyms
PMID27841036-Compound-VII
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0G8HX
 Compound Name 4-Carboxamido-isoindolinone derivative 5 Patented [25]
Synonyms
PMID27841036-Compound-III
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0GH4V
 Compound Name Quinazolinedione derivative 2 Patented [25]
Synonyms
PMID27841036-Compound-12
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.37 nM
External Link
CID: 68388735
TTD: D0IX2C
 Compound Name Quinazolinedione derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-11
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.21 nM
External Link
CID: 66546486
TTD: D0J2SR
 Compound Name Dihydropyrido phthalazinone derivative 2 Patented [25]
Synonyms
PMID27841036-Compound-22
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 800 nM
External Link
CID: 136334008
TTD: D0J4GY
 Compound Name 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2 Patented [25]
Synonyms
PMID27841036-Compound-7
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 26 nM; Kd < 10 nM
External Link
TTD: D0M0WS
 Compound Name Phthalazine derivative 3 Patented [25]
Synonyms
PMID27841036-Compound-19
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 71678316
TTD: D0M9TG
 Compound Name Tetra-hydro-quinoline derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-VIII
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1 to 500 nM
External Link
TTD: D0MP4W
 Compound Name 4-Carboxamido-isoindolinone derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-2
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 20 nM
External Link
TTD: D0O9FC
 Compound Name 4-Carboxamido-isoindolinone derivative 3 Patented [25]
Synonyms
PMID27841036-Compound-4
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 nM
External Link
TTD: D0R0PO
 Compound Name 4-Carboxamido-isoindolinone derivative 4 Patented [25]
Synonyms
PMID27841036-Compound-5
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 20 nM
External Link
TTD: D0Z5DI
 Compound Name Dihydrodiazepinocarbazolone derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-26
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.9 nM
External Link
CID: 71626523
TTD: D0P3YA
 Compound Name Tetra-cyclic pyridophthalazinone derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-25
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5.1 nM
External Link
TTD: D0Z8IR
 Compound Name 3-phenyl isoquinolin-1(2H) derivative 1 Patented [25]
Synonyms
PMID27841036-Compound-20
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 10 nM
External Link
CID: 89588629
TTD: D0TD8R
 Compound Name CPH-102 Preclinical [29]
Synonyms
IABP; INH2BP, Crimson Pharmaceutical; INH2BP, Octamer; PARP inhibitors, Crimson Pharmaceutical; PARP inhibitors, Octamer; CPH-101, Crimson Pharma
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D04ABS
 Compound Name PJ34 Preclinical [30]
Synonyms
344458-19-1; pj-34; N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE; CHEMBL372303; P34; 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide; Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-; UYJZZVDLGDDTCL-UHFFFAOYSA-N; PJ34(free base); 1xk9; SCHEMBL422317; ZINC8960; AC1L1J45; BDBM27497; CTK1B7701; MolPort-035-395-737; Ibrutinib (PCI32765 pound(c); HMS3651B06; BCP07990; HY-13688A; 2662AH; AKOS030229047; SB19292; DB08348; CS-1463; NCGC00370866-10; DA-42692; BC600341
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10.9 nM
External Link
CID: 4858
TTD: D04WDX
DrugBank: DB08348
 Compound Name NU1025 Terminated [31]
MOA Inhibitor
Activity Ki = 48 nM
External Link
CID: 135398517
TTD: D0O3FX
DrugBank: DB02690
 Compound Name 3-Ethynylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL501330; 8-Quinolinecarboxamide, 3-ethynyl-; BDBM50255268
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2300 nM
External Link
CID: 25208746
TTD: D00OZA
 Compound Name 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 289 nM
External Link
CID: 135471356
TTD: D00TUB
 Compound Name N-(4-Phenylthiazol-2-yl)isonicotinamide Investigative [34]
Synonyms
N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide; CHEMBL482012; 5245-66-9; BAS 03572091; AC1Q5OBS; AC1LG7OX; CBMicro_015073; n-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Cambridge id 5245669; Oprea1_303023; Oprea1_553111; SCHEMBL17107144; CTK4J5937; DTXSID30355050; MolPort-001-992-732; ZINC290573; STK483947; BDBM50255300; AKOS000569765; MCULE-9247268363; BIM-0015234.P001; N-(4-Phenyl-thiazol-2-yl)-isonicotinamide; ST50017829; N~4~-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Z27772062
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 753 nM
External Link
CID: 790259
TTD: D00WMC
 Compound Name 5-Chloro-2-methyl-3H-quinazolin-4-one Investigative [35]
MOA Inhibitor
Activity IC50 = 1200 nM
External Link
CID: 135875707
TTD: D01EVX
 Compound Name BZ3 Investigative [36]
Synonyms
5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 13872
TTD: D01RXM
 Compound Name 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide Investigative [31]
Synonyms
2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; CHEMBL134022; BZC; 1efy; AC1L1BMO; SCHEMBL4321727; CTK7A9229; NVVWVYYHTKCIAE-UHFFFAOYSA-N; ZINC11565446; BDBM50093373; DB04010; 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide; 2-(3''-METHOXYPHENYL) BENZIMIDAZOLE-4-CARBOXAMIDE; 2-(3-Methoxy-phenyl)-1H-benzoimidazole-4-carboxylic acid amide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 6 nM
External Link
CID: 1511
TTD: D01YIR
DrugBank: DB04010
 Compound Name CEP-6800 Investigative [37]
Synonyms
UNII-0X7U7SRK9H; 0X7U7SRK9H; CHEMBL247374; 609848-02-4; SCHEMBL12256417; BDBM50197585; 1H-Cyclopenta(a)pyrrolo(3,4-C)carbazole-1,3(2H)-dione, 10-(aminomethyl)-4,5,6,7-tetrahydro-; 8-aminomethyl-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18 nM
External Link
CID: 9948440
TTD: D02GPJ
 Compound Name ANG-2864 Investigative [29]
Synonyms
PARP inhibitor (ischemia/cancer), Angion Biomedica
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D02JHW
 Compound Name 3-Methoxybenzamide Investigative [38]
Synonyms
5813-86-5; m-Methoxybenzamide; m-Anisamide; 3-Methoxy-benzamide; Benzamide, 3-methoxy-; UNII-M8502TLK98; EINECS 227-379-7; NSC 28589; NSC 209527; BRN 2206857; CHEMBL123978; VKPLPDIMEREJJF-UHFFFAOYSA-N; M8502TLK98; 3MB; 3pax; 5-methoxybenzamide; 3-methoxy-benzamid; ACMC-1ASRE; AC1Q5DMC; M-METHOXY BENZAMIDE; bmse000775; 3-Methoxybenzamide, 97%; Oprea1_695428; MLS001066418; 4-10-00-00326 (Beilstein Handbook Reference); cid_98487; SCHEMBL283787; AC1L407F; KS-00000VVU; CTK1H2082; VKPLPDIMEREJJF-UHFFFAOYSA-; DTXSID00206848
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 17000 nM
External Link
CID: 98487
TTD: D02MPP
DrugBank: DB03073
 Compound Name 2-Benzyl-2H-indazole-7-carboxamide Investigative [39]
Synonyms
CHEMBL1094951; SCHEMBL2268172
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 130 nM
External Link
CID: 44549372
TTD: D02QZF
 Compound Name 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative [40]
Synonyms
CHEMBL201723
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5000 nM
External Link
CID: 44407565
TTD: D02XLC
 Compound Name 4-amino-1,8-naphthalimide Investigative [31]
Synonyms
1742-95-6; 4-Aminonaphthalimide; 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE; 6-Amino-1H-benzo[de]isoquinoline-1,3(2H)-dione; 4-Aminonaphthalene-1,8-dicarboximide; Naphthalimide, 4-amino-; DFP 1; 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-; EINECS 217-110-1; BRN 0177185; 6-aminobenzo[de]isoquinoline-1,3-dione; PARP Inhibitor V, 4-ANI; CHEMBL338790; CHEBI:40071; SSMIFVHARFVINF-UHFFFAOYSA-N; 6-Amino-1H-benz(de)isoquinoline-1,3(2H)-dione; 4-AMINO-1,8 NAPHTHALIMIDE
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 26 nM
External Link
CID: 1720
TTD: D03JTS
DrugBank: DB07096
 Compound Name Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione Investigative [40]
Synonyms
CHEMBL373066; pyrroloisoindoledione
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 750 nM
External Link
CID: 44407700
TTD: D03VNZ
 Compound Name 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative [41]
Synonyms
SCHEMBL4662780; CHEMBL363363; BDBM27514; LQEYAIKMIJUZNT-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2a; ZINC13652898; 5,6-Dihydro-5-oxo-8-amino-indeno[1,2-c]isoquinoline
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 300 nM
External Link
CID: 11736764
TTD: D04ATU
 Compound Name EB-47 Investigative [23]
Synonyms
EB 47; 366454-36-6; 5'-Deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine Dihydrochloride; DTXSID40692822; ZINC98052573; NCGC00370771-01; KB-76747; FT-0667818; 4-[1-(6-Amino-9H-purin-9-yl)-1-deoxy-; A-D-ribofuranuronoyl]-N-(2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazineacetamide Dihydrochloride; 2-{4-[(2R,3R,4S,5S)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl}-N-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)acetamide (non-preferred name)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9871899
TTD: D04AYN
 Compound Name BZ6 Investigative [36]
MOA Inhibitor
External Link
CID: 41673734
TTD: D04LDH
 Compound Name 2-(4-methoxyphenyl)quinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL481591; 655222-47-2; CTK1J6622; DTXSID70649086; BDBM50255383; AKOS030560276; 8-Quinolinecarboxamide, 2-(4-methoxyphenyl)-
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1100 nM
External Link
CID: 25209058
TTD: D04TDX
 Compound Name 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative [41]
Synonyms
CHEMBL194155; SCHEMBL4078284; BDBM27515; BIBLEFNXUYTZIB-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2b; ZINC13652899; 5,6-Dihydro-5-oxo-9-amino-indeno[1,2-c]isoquinoline
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 95 nM
External Link
CID: 11288114
TTD: D04UPQ
 Compound Name (E)-N-(4-Phenylthiazol-2-yl) cinnamamide Investigative [34]
Synonyms
CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 224 nM
External Link
CID: 690181
TTD: D04ZQJ
 Compound Name ANG-2684 Investigative [29]
Synonyms
ANG-3038; PARP-1 inhibitors (acute pancreatitis/stroke); PARP-1 inhibitors (acute pancreatitis/stroke), Angion Biomedica
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D05APM
 Compound Name 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative [40]
Synonyms
CHEMBL380940; SCHEMBL5828673
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
CID: 44407566
TTD: D05GMW
 Compound Name 2,3-dihydro-1H-benzo[de]isoquinolin-1-one Investigative [42]
Synonyms
CHEMBL594596; 2,3-dihydro-benzo[de]isoquinolin-1-one; SCHEMBL832168; ZINC24216; BDBM50306285; FCH1866210
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 540 nM
External Link
CID: 10130246
TTD: D05HJG
 Compound Name 5-amino-3,4-dihydroisoquinolin-1(2H)-one Investigative [42]
Synonyms
129075-53-2; CHEMBL594759; SCHEMBL7581623; RTPKPVYTPRJRBY-UHFFFAOYSA-N; ZINC45353622; BDBM50306284; AKOS023598631; AB53700; FCH1123505; KS-9128; CM10348; AJ-110485; 5-amino-3,4-dihydro-1(2H)-isoquinolinone; EN300-254419
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 410 nM
External Link
CID: 18369509
TTD: D05RXG
 Compound Name KR-33889 Investigative [29]
Synonyms
KR-34285; PARP-1 inhibitors (myocardial infarction), KRICT
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D05SYO
 Compound Name 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one Investigative [43]
Synonyms
CHEMBL194684
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 119 nM
External Link
CID: 44403402
TTD: D05WYN
 Compound Name AG-014376 Investigative [44]
Synonyms
CHEMBL361489; SCHEMBL7159231; BDBM50154730; 6-(4-Dimethylaminomethyl-phenyl)-3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-one
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 6.4 nM
External Link
CID: 9797108
TTD: D05XMG
 Compound Name 3-Hydroxy-benzamide Investigative [33]
Synonyms
3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 9100 nM
External Link
CID: 342403
TTD: D05ZTI
 Compound Name 8-Methoxy-2-phenyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 > 10000 nM
External Link
CID: 135439437
TTD: D06NKJ
 Compound Name Quinoline-8-carboxamide Investigative [32]
Synonyms
8-Quinolinecarboxamide; 55706-61-1; CCRIS 6967; CHEMBL502330; HPQRQAOVNXWEEQ-UHFFFAOYSA-N; 8-Carbamoylquinoline; 8-Quinolinecarboxamide #; AC1L44SC; SCHEMBL460456; CTK5A4047; quinoline-8-carboxylic acid amide; DTXSID00204243; MolPort-005-722-305; ZINC6095019; BDBM50255266; AKOS008969900; NE38855; MCULE-7978956907; LS-188644; KB-259682
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1900 nM
External Link
CID: 150664
TTD: D07AGU
 Compound Name 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative [41]
Synonyms
CHEMBL190895; BDBM27513; indeno[1,2-c]isoquinolinone, 1e; 9-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 180 nM
External Link
CID: 25190932
TTD: D07BBR
 Compound Name 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 104 nM
External Link
CID: 135457978
TTD: D07BPT
 Compound Name 2H-Isoquinolin-1-one Investigative [33]
Synonyms
1-Hydroxyisoquinoline; 491-30-5; Isoquinolin-1(2H)-one; isoquinolin-1-ol; 1-Isoquinolinol; Isocarbostyril; 1(2H)-ISOQUINOLINONE; Isoquinolin-1-one; 489453-23-8; 1(2H)-Isoquinolone; 1,2-dihydroisoquinolin-1-one; 1-hydroxyisoquinolin; isoquinolinol; 87602-67-3; 1(2H)-ISOQUINILONE; Isocarbostyril, 98%; UNII-95EG3HGG1P; 95EG3HGG1P; Isoquinolinone; CHEMBL339695; CHEBI:18350; VDBNYAPERZTOOF-UHFFFAOYSA-N; 1-isoquinolone; oxidoisoquinolinium; EINECS 207-732-1; Isocarbostyril(1-hydroxyisoquinoline); NSC 27273
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 9 nM
External Link
CID: 10284
TTD: D07CRG
 Compound Name KU-58684 Investigative [34]
Synonyms
SCHEMBL863338; 623578-11-0
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11725479
TTD: D07QPV
 Compound Name 2,8-Dimethyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 490 nM
External Link
CID: 135463574
TTD: D07SRJ
 Compound Name 5-aminoisoquinolin-1(2H)-one Investigative [32]
Synonyms
93117-08-9; 5-amino-2H-isoquinolin-1-one; 5-AMINOISOQUINOLIN-1-OL; 5-amino-1,2-dihydroisoquinolin-1-one; 5-AIQ; CHEMBL446240; 5-Amino-2H-isoquinoin-1-one; 5-AMINO-1(2H)-ISOQUINOLINONE; 5-aminoisoquinolinone; 4pnq; 32X; AC1Q6DVG; AC1L1CUR; 5-Amino-1-isoquinolinol; SCHEMBL215327; 5-Amino-1-hydroxyisoquinoline; BDBM27503; 5-amino-isoquinolin-1(2h)-one; 5-amino isoquinolin-1(2h)-one; CTK5H2122; DTXSID90274354; 1(2H)-Isoquinolinone,5-amino-; MolPort-008-423-043; MolPort-004-803-197
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 940 nM
External Link
CID: 2072
TTD: D07WPL
 Compound Name INO-1002 Investigative [29]
Synonyms
PARP inhibitors, Inotek; PARP inhibitor (erectile dysfunction), Inotek; PARP inhibitor (prostate nerve damage), Inotek; Poly (ADP ribose) polymerase inhibitor (erectile dysfunction), Inotek; Poly (ADP ribose) polymerase inhibitor (prostate nerve damage), Inotek
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D08AOV
 Compound Name 3-(4-aminophenyl)quinoxaline-5-carboxamide Investigative [34]
Synonyms
CHEMBL443077; quinoxaline analogue, 3f; SCHEMBL7112515
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 87 nM
External Link
CID: 25218519
TTD: D08GMO
 Compound Name 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide Investigative [39]
Synonyms
2-phenylpyrazolo[1,5-a]pyridine-7-carboxamide; 1196713-16-2; ZINC64337832; DA-47424
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 49799912
TTD: D08OUR
 Compound Name 4-benzylphthalazin-1(2H)-one Investigative [34]
Synonyms
4-Benzyl-1(2H)-phthalazinone; 32003-14-8; 4-Benzyl-2H-phthalazin-1-one; 4-benzyl-1,2-dihydrophthalazin-1-one; CHEMBL66761; JUCCMEHWBGPJKS-UHFFFAOYSA-N; benzylphthalazinone; phthalazinone, 1; 4-benzyl-phthalazone; AC1LDDNC; SMR000135223; AC1Q6GZZ; ChemDiv2_000142; Cambridge id 5241846; Oprea1_151142; Oprea1_623913; CBDivE_015258; MLS000530246; SCHEMBL863462; CTK4G8063; BDBM27660; DTXSID30346948; MolPort-001-796-654; HMS2379K10; HMS1369G10; 4-benzyl-2-hydrophthalazin-1-one; 4-Benzyl-1(2H)-phthalazinone #
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 770 nM
External Link
CID: 616651
TTD: D08QWR
 Compound Name 3-Methylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL504998; 8-Quinolinecarboxamide, 3-methyl-; BDBM50255267
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3400 nM
External Link
CID: 25208598
TTD: D08XPZ
 Compound Name 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide Investigative [38]
Synonyms
3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE; 4tju; 1wok; AC1LCVX7; quinoxaline analogue, 3b; SCHEMBL424209; 3-(4-chloro-phenyl)-quinoxaline-5-carboxylic acid amide; CTK8F4675; BDBM27720; ZINC1489510; DB03509; 489457-67-2
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 657038
TTD: D08ZVM
DrugBank: DB03509
 Compound Name 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 891 nM
External Link
CID: 135407310
TTD: D0B2WX
 Compound Name HYDAMTIQ Investigative [29]
Synonyms
PARP-1 inhibitor (brain ischemia), University of Perugia
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0CA2S
 Compound Name 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative [41]
Synonyms
SCHEMBL4661629; CHEMBL370673; BDBM27510; SWBDUXDIPMGDNO-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 1b; ZINC13652894; 5,6-dihydro-5-oxo-8-nitro-indeno[1,2-c]isoquinoline; 8-Nitro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 25190929
TTD: D0E0QT
 Compound Name PD-128763 Investigative [38]
Synonyms
5-Methyl-3,4-dihydroisoquinolin-1(2H)-one; 129075-56-5; 3,4-Dihydro-5-methyl-1(2H)-isoquinolinone; 3,4-DIHYDRO-5-METHYL-ISOQUINOLINONE; 1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl-; CHEBI:41928; PD128763; CHEMBL125200; 5-methyl-3,4-dihydro-2H-isoquinolin-1-one; 3,4-dihydro-5-methylisoquinolinone; 1(2H)-Isoquinolinone,3,4-dihydro-5-methyl-; 5-methyl-1,2,3,4-tetrahydroisoquinolin-1-one; DHQ; PD 128763; dihydroisoquinolinone, 1; AC1L3WIO; ACMC-1C7L4; SCHEMBL831538; AMBZ0075; KS-00000QFP; CTK4B6146; BDBM27682
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 70 nM
External Link
CID: 148140
TTD: D0E2VC
DrugBank: DB03722
 Compound Name 8-Methyl-2-phenyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 795 nM
External Link
CID: 135531482
TTD: D0E5EW
 Compound Name TI3 Investigative [36]
Synonyms
RB106; CHEMBL419499; [(2S)-2-SULFANYL-3-PHENYLPROPANOYL]-GLY-(5-PHENYLPROLINE); 1qf2; AC1L9LL2; BDBM50051785; DB02669; N-[(S)-2-Mercapto-3-phenylpropionyl]-Gly-[(5R)-5-phenyl-L-Pro-]-OH; N-[(2S)-3-phenyl-2-sulfanylpropanoyl]glycyl-(5R)-5-phenyl-L-proline; (2S,5R)-5-phenyl-1-[2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid; (2S,5R)-1-[2-((S)-2-Mercapto-3-phenyl-propionylamino)-acetyl]-5-phenyl-pyrrolidine-2-carboxylic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 448087
TTD: D0E7UW
DrugBank: DB02669
 Compound Name 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one Investigative [34]
Synonyms
CHEMBL106154; Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino-; SCHEMBL12750402; BDBM50130580; 433726-73-9
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 180 nM
External Link
CID: 16221809
TTD: D0EI6X
 Compound Name S-111 Investigative [29]
Synonyms
PARP1 inhibitor (cancer), Sentinel Oncology
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0EQ1J
 Compound Name Thieno-phenanthridin-6-one Investigative [23]
MOA Inhibitor
External Link
TTD: D0EW8Y
 Compound Name 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one Investigative [43]
Synonyms
CHEMBL194535
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 23 nM
External Link
CID: 44403357
TTD: D0F8ZI
 Compound Name 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one Investigative [34]
Synonyms
CHEMBL84044; 7403-93-2; NSC403412; AC1L83AN; SCHEMBL6645911; DTXSID70323238; BDBM50131013; NSC-403412; 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one; 1,3,4,4a,5,10b-Hexahydro-2H-phenanthridin-6-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7500 nM
External Link
CID: 345678
TTD: D0FF4M
 Compound Name 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 105 nM
External Link
CID: 135492389
TTD: D0G5VD
 Compound Name 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 504 nM
External Link
CID: 135463623
TTD: D0GA0Y
 Compound Name 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one Investigative [43]
Synonyms
CHEMBL373210
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 950 nM
External Link
CID: 44403404
TTD: D0GJ8U
 Compound Name 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide Investigative [39]
Synonyms
CHEMBL1096560; SCHEMBL2265205
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 71 nM
External Link
CID: 44549505
TTD: D0I2AF
 Compound Name 2-phenyl-2H-indazole-7-carboxamide Investigative [39]
Synonyms
CHEMBL594298; SCHEMBL1422404; BDBM50306166
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 24 nM
External Link
CID: 44549251
TTD: D0IX3I
 Compound Name Carba-Nicotinamide-Adenine-Dinucleotide Investigative [38]
Synonyms
Carba-NAD; Carbanicotinamide adenine dinucleotide; 112345-60-5; AC1L4TS7; AC1Q5J0L; SCHEMBL16445201; 5'-o-{[({[(1r,2r,3s,4r)-4-(3-carbamoylpyridinium-1-yl)-2,3-dihydroxycyclopentyl]methoxy}phosphinato)oxy](hydroxy)phosphoryl}adenosine; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-((4-(3-(aminocarbonyl)pyridinio)-2,3-dihydroxycyclopentyl)m
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 163884
TTD: D0JD1O
DrugBank: DB02498
 Compound Name 3-aminobenzamide Investigative [30]
Synonyms
3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 3100 nM
External Link
CID: 1645
TTD: D0K2PD
 Compound Name 3-Ethenylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL481793; 8-Quinolinecarboxamide, 3-ethenyl-; BDBM50255270
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5800 nM
External Link
CID: 25208747
TTD: D0K7JT
 Compound Name 3-Phenylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL450259; BDBM50255264
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 15000 nM
External Link
CID: 25208596
TTD: D0L1NQ
 Compound Name 3-(4-methoxyphenyl)quinoxaline-5-carboxamide Investigative [34]
Synonyms
CHEMBL519443; quinoxaline analogue, 3e; SCHEMBL7045177
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 71 nM
External Link
CID: 9965481
TTD: D0L1RZ
 Compound Name TI4 Investigative [36]
MOA Inhibitor
External Link
CID: 91808049
TTD: D0L6LO
 Compound Name Benzo[c][1,5]naphthyridin-6(5H)-one Investigative [34]
Synonyms
CHEMBL320031; Benzo[c]-1,5-naphthyridin-6(5H)-one; SCHEMBL12750384; BDBM50130585; 5H-Benzo[c][1,5]naphthyridin-6-one; Benzo[c][1,5]naphthyridine-6(5H)-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 116 nM
External Link
CID: 10535869
TTD: D0M6WJ
 Compound Name 3-(4-cyanophenyl)quinoxaline-5-carboxamide Investigative [34]
Synonyms
CHEMBL481603; quinoxaline analogue, 3c; SCHEMBL7108289
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 101 nM
External Link
CID: 25218518
TTD: D0M9TW
 Compound Name 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione Investigative [40]
Synonyms
CHEMBL201907; SCHEMBL2086780; ZINC28569089
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 40 nM
External Link
CID: 11506860
TTD: D0NU5Z
 Compound Name 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one Investigative [41]
Synonyms
CHEMBL370045; BDBM27512; indeno[1,2-c]isoquinolinone, 1d; ZINC13652896; 8-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 225 nM
External Link
CID: 25190931
TTD: D0O0GA
 Compound Name 8-Hydroxy-2-phenyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 1034 nM
External Link
CID: 135528341
TTD: D0O6WW
 Compound Name 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 > 10000 nM
External Link
CID: 135417274
TTD: D0OF1I
 Compound Name 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide Investigative [39]
Synonyms
CHEMBL1099295; SCHEMBL2264064
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 24 nM
External Link
CID: 44549375
TTD: D0PT1K
 Compound Name BPI-704001 Investigative [29]
Synonyms
BPI-705001; BPI-715001; PARP-1 inhibitors (cancer); PARP-1 inhibitors (cancer), Beta Pharma
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0R7FS
 Compound Name Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Investigative [40]
Synonyms
CHEMBL370869; SCHEMBL5381581
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10000 nM
External Link
CID: 18382004
TTD: D0R7HU
 Compound Name 2-Methylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL471966; 8-Quinolinecarboxamide, 2-methyl-; SCHEMBL422282; BDBM50255329; AKOS022882220
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 21195867
TTD: D0S8HZ
 Compound Name 8-Methoxy-2-methyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
External Link
CID: 135411146
TTD: D0T3SY
 Compound Name 3-Prop-1-ynylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL504903; ZINC40829471
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2200 nM
External Link
CID: 25208905
TTD: D0T5TT
 Compound Name 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide Investigative [39]
Synonyms
CHEMBL1094952; SCHEMBL2265265
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 nM
External Link
CID: 44549373
TTD: D0TH7S
 Compound Name 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one Investigative [35]
MOA Inhibitor
Activity IC50 = 1100 nM
External Link
CID: 135508369
TTD: D0U5WY
 Compound Name 3-Ethylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL453989; 8-Quinolinecarboxamide, 3-ethyl-; BDBM50255269
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3700 nM
External Link
CID: 25208904
TTD: D0UF0U
 Compound Name A-620223 Investigative [29]
Synonyms
A-866111; A-966492; ABT-472; ABT-999; PARP inhibitor, Abbott; PARP inhibitors, Abbott; Poly (ADP)ribose polymer inhibitor, Abbott; Poly (ADP)ribose inhibitors (cancer), Abbott
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 3 nM
External Link
CID: 9925908
TTD: D0VY5O
DrugBank: DB07330
 Compound Name DR2313 Investigative [23]
MOA Inhibitor
External Link
CID: 135522417
TTD: D0W7XH
DrugBank: DB07677
 Compound Name 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
External Link
CID: 135547083
TTD: D0WO3P
 Compound Name 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide Investigative [39]
Synonyms
CHEMBL1094953; SCHEMBL2265628
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 14 nM
External Link
CID: 44549374
TTD: D0XZ5D
 Compound Name 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one Investigative [33]
MOA Inhibitor
Activity IC50 = 1200 nM
External Link
CID: 135471354
TTD: D0Y1MH
 Compound Name 2-ethylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL526128; 8-Quinolinecarboxamide, 2-ethyl-; BDBM50255330
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 800 nM
External Link
CID: 25208752
TTD: D0Z3PB
 Compound Name 2-phenylquinoline-8-carboxamide Investigative [32]
Synonyms
CHEMBL480429; SCHEMBL6442515; ZINC3939668
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 900 nM
External Link
CID: 44156952
TTD: D0Z9DY
 Compound Name BZ5 Investigative [36]
MOA Inhibitor
External Link
CID: 46241905
TTD: D0ZK3L
 Compound Name ME0328 Investigative [45]
Synonyms
ME-0328; compound 5b [PMID 24188023]
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6300 nM
External Link
CID: 135566764
TTD: D04QRM
 Compound Name [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala Investigative [36]
Synonyms
TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5289469
TTD: D09SZG
DrugBank: DB02597
 Compound Name S-070 Investigative [29]
Synonyms
S-158; Targeted synergy program (solid tumor), Sentinel Oncology; Chk1/PARP-1 inhibitors (cancer); Chk1/PARP-1 inhibitors (cancer), Sentinel Oncology
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0P4DG
2B72: Gastric cancer 81 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Leniolisib Approved [46]
Synonyms
1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ
    Click to Show/Hide
External Link
CID: 57495353
TTD: DGO2C1
 Compound Name Atezolizumab Approved [5]
External Link
TTD: D0YM2K
 Compound Name Bavencio Approved [5]
External Link
TTD: D0W8HN
 Compound Name Tebentafusp Approved [47]
External Link
TTD: D0S0BJ
 Compound Name Merimepodib Approved [48]
Synonyms
Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
    Click to Show/Hide
External Link
CID: 153241
TTD: D0F0ZE
DrugBank: DB04862
 Compound Name Taxol Approved [49]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Ramucirumab Approved [50]
Synonyms
LY3009806
    Click to Show/Hide
External Link
TTD: D09HVD
 Compound Name Tucatinib Approved [51]
Synonyms
Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
    Click to Show/Hide
External Link
CID: 51039094
TTD: D09GRX
DrugBank: DB11652
 Compound Name Antacids Approved [52]
External Link
TTD: D06AJL
 Compound Name Trastuzumab Approved [5]
Synonyms
Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
    Click to Show/Hide
External Link
TTD: D04WFL
 Compound Name Carbamazepine Phase 3 [53]
Synonyms
Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
    Click to Show/Hide
External Link
CID: 2554
TTD: D04MSM
DrugBank: DB00564
 Compound Name Margetuximab Approved [5]
External Link
TTD: D01YYP
 Compound Name Nivolumab Approved [5]
External Link
TTD: D00GOV
 Compound Name GRANITE Phase 3 [54]
Synonyms
Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-
    Click to Show/Hide
External Link
CID: 11784975
TTD: DKF9I3
 Compound Name Zolbetuximab Phase 3 [55]
Synonyms
IMAB362
    Click to Show/Hide
External Link
TTD: D4HQ1F
 Compound Name Tusamitamab ravtansine Phase 3 [56]
Synonyms
SAR408701
    Click to Show/Hide
External Link
TTD: D2D6NJ
 Compound Name Andecaliximab Phase 3 [57]
External Link
TTD: D0Z6SP
 Compound Name ABP 980 Phase 3 [58]
External Link
TTD: D0WZ0X
 Compound Name GS-5745 Phase 3 [49]
External Link
CID: 56776542
TTD: D0WL0Q
 Compound Name S-1 Phase 3 [59]
Synonyms
Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)
    Click to Show/Hide
External Link
CID: 163872
TTD: D0S8LJ
 Compound Name Lonsurf Phase 3 [5]
External Link
TTD: D0PM0Y
 Compound Name GDC-0068 Phase 3 [49]
Synonyms
RG7440
    Click to Show/Hide
External Link
CID: 24788740
TTD: D0I4TH
DrugBank: DB11743
 Compound Name Edotecarin Phase 3 [60]
Synonyms
ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
    Click to Show/Hide
External Link
CID: 9808998
TTD: D0I1DW
DrugBank: DB04882
 Compound Name RG3638 Phase 3 [61]
Synonyms
Onartuzumab
    Click to Show/Hide
External Link
TTD: D0H9PT
 Compound Name G17DT Phase 3 [62]
Synonyms
Gastrimmune; Insegia
    Click to Show/Hide
External Link
TTD: D0G8ZQ
 Compound Name DE-766 Phase 3 [63]
External Link
TTD: D0FJ1W
 Compound Name Tesetaxel Phase 2 [64]
Synonyms
DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
    Click to Show/Hide
External Link
CID: 6918574
TTD: D0F9VH
DrugBank: DB12019
 Compound Name Nelipepimut S Phase 3 [65]
Synonyms
E75
    Click to Show/Hide
External Link
CID: 9941306
TTD: D0F8UV
 Compound Name BMS-986205 Phase 3 [5]
Synonyms
KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
    Click to Show/Hide
External Link
CID: 121328278
TTD: D0DP5I
DrugBank: DB14986
 Compound Name Rivoceranib Phase 3 [5]
External Link
TTD: D0D7BX
 Compound Name Claudiximab Phase 3 [5]
Synonyms
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
    Click to Show/Hide
External Link
TTD: D0B3ZC
 Compound Name OS-440 Phase 3 [66]
Synonyms
CNS modulator (spasticity), Osmotica
    Click to Show/Hide
External Link
TTD: D09OHH
 Compound Name Oraxol Phase 3 [5]
External Link
TTD: D04UWU
 Compound Name ICI 118,551 Phase 3 [49]
Synonyms
Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
    Click to Show/Hide
External Link
CID: 3682
TTD: D04DJS
 Compound Name Evorpacept Phase 2/3 [67]
Synonyms
ALX148
    Click to Show/Hide
External Link
TTD: DRP8H0
 Compound Name BNT141 Phase 2 [68]
External Link
TTD: DFZ19J
 Compound Name Anti-LAG3 Phase 2 [58]
External Link
TTD: D0T7OI
 Compound Name GSK1292263 Phase 2 [69]
External Link
CID: 24996872
TTD: D0S4II
DrugBank: DB12627
 Compound Name MM-111 Phase 2 [70]
External Link
TTD: D0Q2KM
 Compound Name Plevitrexed Phase 2 [71]
Synonyms
ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,
    Click to Show/Hide
External Link
CID: 135430970
TTD: D0I9GR
DrugBank: DB06163
 Compound Name DS-8201 Phase 1 [58]
Synonyms
9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-
    Click to Show/Hide
External Link
CID: 10671
TTD: D0E8IQ
 Compound Name XL880 Phase 2 [72]
Synonyms
GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
    Click to Show/Hide
External Link
CID: 42642645
TTD: D0D1GF
DrugBank: DB12307
 Compound Name Matuzumab Phase 2 [73]
Synonyms
EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0BZ7V
 Compound Name BAY-57-9352 Phase 2 [49]
Synonyms
Telatinib; Bay 57-9352
    Click to Show/Hide
External Link
CID: 9808844
TTD: D07NOI
DrugBank: DB15393
 Compound Name Bemarituzumab Phase 2 [74]
External Link
TTD: D05ISO
 Compound Name PEGPH20 Phase 2 [5]
External Link
TTD: D05INV
 Compound Name Plevitrexed (R)-isomer Phase 2 [75]
Synonyms
YW3548
    Click to Show/Hide
External Link
CID: 213022
TTD: D04FYZ
 Compound Name APR-246 Phase 2 [76]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name CRS-207 Phase 2 [65]
External Link
TTD: D02WSB
 Compound Name Opdivo + Yervoy Phase 3 [5]
External Link
TTD: D02VYE
 Compound Name CT-041 Phase 1/2 [77]
External Link
TTD: DJ6AW5
 Compound Name BPX-601 Phase 1/2 [78]
External Link
TTD: D0TY6U
 Compound Name Anti-MUC1 CAR-T cells Phase 1/2 [79]
External Link
TTD: D0C9MJ
 Compound Name Anti-Mesothelin CAR-T cells Phase 1/2 [80]
External Link
TTD: D0BE6M
 Compound Name Anti-HER2 CAR-T Phase 1/2 [81]
External Link
TTD: D08QZH
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [82]
External Link
TTD: D08QYW
 Compound Name PAT-SC1 Phase 1/2 [83]
Synonyms
SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab
    Click to Show/Hide
External Link
TTD: D00UOQ
 Compound Name ASP2138 Phase 1 [84]
External Link
TTD: DTQL30
 Compound Name SAR443216 Phase 1 [85]
External Link
TTD: DL6F3E
 Compound Name AMG 199 Phase 1 [86]
External Link
TTD: DEP3Z8
 Compound Name AMG 910 Phase 1 [87]
External Link
TTD: DEDP81
 Compound Name Alofanib Phase 1 [88]
Synonyms
1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
    Click to Show/Hide
External Link
CID: 86280646
TTD: D47MOS
 Compound Name HER2-specific CAR T cell Phase 1 [89]
External Link
TTD: D0YF6K
 Compound Name Anti-CEA-CAR T Phase 1 [90]
External Link
TTD: D0S1QN
 Compound Name XR-5944 Phase 1 [91]
Synonyms
MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942
    Click to Show/Hide
External Link
CID: 439035
TTD: D0Q5TH
DrugBank: DB06364
 Compound Name A168 Phase 1 [92]
External Link
TTD: D0L9PU
 Compound Name EGFR806-specific CAR T cell Phase 1 [93]
External Link
TTD: D0I7ZH
 Compound Name AbGn-107 Phase 1 [5]
External Link
TTD: D08GZE
 Compound Name FPA144 Phase 1 [58]
External Link
TTD: D06NND
 Compound Name Minnelide 001 Phase 1 [49]
External Link
TTD: D05UFJ
 Compound Name CAR-T cells targeting EpCAM Phase 1 [94]
External Link
TTD: D01TNK
 Compound Name Anti-CEA CAR-T cells Phase 1 [95]
External Link
TTD: D00KDQ
 Compound Name EPCAM-targeted CAR-T cells Clinical trial [96]
External Link
TTD: D0T8DD
 Compound Name PMID28460551-Compound-1 Patented [97]
External Link
CID: 25190990
TTD: D0IH3I
DrugBank: DB14866
 Compound Name Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 Patented [98]
Synonyms
PMID28621580-Compound-WO2012084683c62
    Click to Show/Hide
External Link
TTD: D04PKQ
 Compound Name TOPIXANTRONE HYDROCHLORIDE Discontinued in Phase 2 [99]
Synonyms
SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride
    Click to Show/Hide
External Link
CID: 6918273
TTD: D06DWQ
 Compound Name MDL 101,731 Discontinued in Phase 2 [100]
Synonyms
Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331
    Click to Show/Hide
External Link
CID: 6435808
TTD: D05HZI
DrugBank: DB06433
 Compound Name BBR-3438 Discontinued in Phase 2 [101]
Synonyms
Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438
    Click to Show/Hide
External Link
CID: 3038512
TTD: D01VPR
 Compound Name IPI-493 Discontinued in Phase 1 [102]
Synonyms
[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851
    Click to Show/Hide
External Link
CID: 9893658
TTD: D0BM6S
DrugBank: DB13023
 Compound Name Kanjinti Application submitted [5]
External Link
TTD: D0CW3U
 Compound Name Anti-CD9 mab Investigative [103]
Synonyms
ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University
    Click to Show/Hide
External Link
TTD: D09BPT
References
Ref 1 Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer. Aging (Albany NY). 2021 Apr 21;13(8):12224-12238. doi: 10.18632/aging.103822. Epub 2021 Apr 21.
Ref 2 METTL3 promotes oxaliplatin resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135. doi: 10.1007/s00018-022-04129-0.
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 4 Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. doi: 10.1080/14712598.2019.1572746. Epub 2019 Jan 29.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. doi: 10.1038/s41573-020-00108-x. Epub 2021 Jan 19.
Ref 7 ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
Ref 8 National Cancer Institute Drug Dictionary (drug id 756211).
Ref 9 Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665. doi: 10.1021/acs.jmedchem.7b01375. Epub 2017 Dec 27.
Ref 10 Clinical pipeline report, company report or official report of HaiHe Biopharma.
Ref 11 EZH2 inhibitors: a patent review (2014-2016). Expert Opin Ther Pat. 2017 Jul;27(7):797-813. doi: 10.1080/13543776.2017.1316976. Epub 2017 Apr 20.
Ref 12 Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015). Expert Opin Ther Pat. 2016;26(3):309-22. doi: 10.1517/13543776.2016.1146252. Epub 2016 Feb 16.
Ref 13 A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6. doi: 10.1038/nchembio.1084. Epub 2012 Sep 30.
Ref 14 Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. doi: 10.1073/pnas.1210371110. Epub 2012 Dec 10.
Ref 15 An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-34. doi: 10.1021/cb400133j. Epub 2013 Apr 24.
Ref 16 Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. doi: 10.1021/ml3003346. eCollection 2012 Dec 13.
Ref 17 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 18 beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59. doi: 10.1080/15257770902865415.
Ref 19 Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11. doi: 10.1021/jm900052j.
Ref 20 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 21 Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
Ref 22 Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3. doi: 10.1021/jm0255769.
Ref 23 Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. doi: 10.1038/nrd1718.
Ref 24 Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.
Ref 25 PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert Opin Ther Pat. 2017 Mar;27(3):363-382. doi: 10.1080/13543776.2017.1259413. Epub 2016 Nov 21.
Ref 26 Clinical pipeline report, company report or official report of Allarity Therapeutics.
Ref 27 AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. eCollection 2020.
Ref 28 NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843.
Ref 29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
Ref 30 Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001 Jan;7(1):108-13. doi: 10.1038/83241.
Ref 31 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 32 Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor. J Med Chem. 2009 Feb 12;52(3):868-77. doi: 10.1021/jm8013629.
Ref 33 Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J Med Chem. 1998 Dec 17;41(26):5247-56. doi: 10.1021/jm980273t.
Ref 34 Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. doi: 10.1021/jm800902t.
Ref 35 Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem. 2004 Aug 12;47(17):4151-4. doi: 10.1021/jm0499256.
Ref 36 Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
Ref 37 Novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2007 Jan 15;17(2):542-5. doi: 10.1016/j.bmcl.2006.10.010. Epub 2006 Oct 10.
Ref 38 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 39 Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85. doi: 10.1021/jm901188v.
Ref 40 Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42. doi: 10.1016/j.bmcl.2005.10.099. Epub 2005 Nov 15.
Ref 41 Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3. doi: 10.1021/jm0502891.
Ref 42 Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52. doi: 10.1016/j.bmcl.2009.12.002. Epub 2009 Dec 4.
Ref 43 4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5. doi: 10.1016/j.bmcl.2005.06.094.
Ref 44 Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem. 2004 Oct 21;47(22):5467-81. doi: 10.1021/jm030513r.
Ref 45 Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem. 2013 Dec 12;56(23):9556-68. doi: 10.1021/jm401394u. Epub 2013 Nov 22.
Ref 46 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217759.
Ref 47 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228.
Ref 48 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 49 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7390).
Ref 51 ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
Ref 52 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 53 ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT00879333) Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
Ref 56 ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT02545504) Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1). U.S. National Institutes of Health.
Ref 58 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 59 Clinical pipeline report, company report or official report of Taiho Pharma U.S.A.
Ref 60 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
Ref 61 ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.
Ref 62 ClinicalTrials.gov (NCT02118077) Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 63 Clinical pipeline report, company report or official report of Daiichi Sankyo.
Ref 64 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 65 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031678)
Ref 67 ClinicalTrials.gov (NCT05002127) A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). U.S.National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 69 ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.
Ref 70 ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
Ref 71 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8278).
Ref 72 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
Ref 73 ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
Ref 74 ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
Ref 75 Clinical pipeline report, company report or official report of plevitrexed.
Ref 76 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
Ref 77 ClinicalTrials.gov (NCT04404595) Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers. U.S.National Institutes of Health.
Ref 78 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 79 ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Ref 80 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 81 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 82 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013314)
Ref 84 ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
Ref 85 Clinical pipeline report, company report or official report of Sanofi
Ref 86 ClinicalTrials.gov (NCT04117958) Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
Ref 87 ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health.
Ref 88 ClinicalTrials.gov (NCT04071184) Study of Alofanib in Patients With Metastatic Gastric Cancer. U.S. National Institutes of Health.
Ref 89 ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Ref 90 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 91 Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
Ref 92 Clinical pipeline report, company report or official report of Klus Pharma
Ref 93 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Ref 94 ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
Ref 95 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 96 ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
Ref 97 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 98 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. doi: 10.1080/13543776.2017.1344215. Epub 2017 Jun 23.
Ref 99 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
Ref 100 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002544)
Ref 101 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)
Ref 102 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026781)
Ref 103 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.